-
Mashup Score: 4
You are now leaving AstraZeneca-us.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Important notice for users You are about to access
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Green patients, healthy planet - 13 day(s) ago
In March 2024, health and climate leaders gathered in Miami at the Aspen Ideas: Climate conference for a roundtable discussion, hosted by AstraZeneca and the Na tional Academy of Medicine, that explored concrete actions to address the climate-health nexus and build climate-resilient health systems that improve health outcomes for all. The climate crisis is the largest public health crisis of our time. From air pollution to flooding, extreme heat to drought, climate change is increasing levels of ill
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet-
At @aspen_climate, we hosted a roundtable discussion with @theNAMedicine on the interconnected issues of climate & health. Learn about the actionable insights to help accelerate progress & guide future partnerships, programs, & policies on these issues. https://t.co/C2S74GAlwy https://t.co/oVrBQaNcxL
-
-
Mashup Score: 3That's Understandable - 14 day(s) ago
Tune in to this episode as we examine the delicate balance between fostering innovation and ensuring access to groundbreaking therapies for patients. In each episode, AstraZeneca’s US Head of External Communications, Brendan McEvoy, sits down with the various experts to break down the multitude of factors affecting the healthcare industry. Brendan interviews AstraZeneca’s US President, Joris Silon. The two discuss climate change, health equity, the economy, superpowers, gardening and disco. In this
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 12The Crucial Role of Genetic Testing in Amyloidosis - 27 day(s) ago
What is Hereditary ATTR (hATTR)? Hereditary transthyretin-mediated amyloidosis (hATTR) is an inherited genetic condition affecting a protein called transthyretin (TTR). 1 A variant in the TTR gene causes the protein to become abnormally shaped and misfolded. This misfolded TTR forms amyloid fibrils which can build up and deposit in the nerves, digestive system, heart and other tissues and organs, causing a variety of symptoms such as numbness, pain or tingling in the hands and feet, shortness of breath,
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SCLC) is a highly aggressive form of lung
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the US Food and Drug Administration (FDA) action date for its regulatory decision, is during
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0
Whether you are scheduling a routine check-up or looking to better understand your current condition, the average person in the United States waits approximately 26 days before they’re able to see their primary care provider (PCP) in person – and the process can be even more complicated for the 30% of patients who don’t have a PCP. 1 A lack of structure or tools to support health literacy, need for savings program support, and geographic challenges to accessing appropriate care can create additional
Source: www.astrazeneca-us.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 3
Latest analysis of the results from the DUO-E Phase III trial showed IMFINZI ® (durvalumab) plus platinum-based chemotherapy followed by IMFINZI plus LYNPARZA ® (olaparib) (LYNPARZA and IMFINZI arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone. These results will be presented today in a late-breaking session at the 2024 Society of Gynecologic
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Understanding ATTR: The Challenges of Amyloidosis - 2 month(s) ago
Transthyretin amyloidosis (ATTR) is a complex medical condition that happens when a protein called transthyretin (TTR) does something different than what it’s supposed to do in the body. Normally, TTR is a four-piece protein produced mostly in the liver that helps carry important substances, like thyroxine (thyroid hormones) and vitamin A, throughout the body. When someone has ATTR, the pieces of TTR fall apart, misfold, and change shape. These pieces bind together to form larger structures called
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
Today, we shared positive high-level results from the ECHO Phase III trial in people with previously untreated #MantleCellLymphoma. Read about the results here: https://t.co/BXPCY1mXY7 #MCL #BloodCancer https://t.co/pqVuUowRo9